UBS has given Carl Zeiss Meditec a "Neutral" rating and a target price of 65 euros.
Analyst Graham Doyle has expressed concerns about the European medical technology sector, which has underperformed the overall market this year. Doyle's sales and earnings forecasts for 2025 are lower than the consensus estimates for 10 out of the 17 sector stocks he covers, indicating a cautious outlook for the industry.
This commentary, published on November 26, 2024, highlights the challenges faced by medical technology shares in the current market environment.